Peripheral Neuropathy Related to Chemotherapy

Wilkes, Gail M.

doi:10.1016/j.soncn.2007.05.001

Cited by 70 publications

(74 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Visvosky [157] opined on the need for future research on physical activity, "Physical activity interventions with larger sample sizes and of longer duration are necessary to achieve long-term health outcomes. Physical activity interventions that include the older or more obese women with breast cancer are also needed, as this population may be most at risk of functional decline and the development of chronic illness.…”

Section: Discussionmentioning

confidence: 99%

Assessment and Treatment of Chemotherapy-induced Peripheral Neuropathy- a Physical Therapy Perspective

Kumar

Jamwal

2015

GJCT

View full text Add to dashboard Cite

Chemotherapy is recognized as a mainline treatment for all types of cancer, and its most debilitating and dose-limiting complication is Chemotherapy-induced peripheral neuropathy (CIPN), the mechanisms of nerve damage of which depends upon the specific chemotherapeutic agent used. Use of non-invasive treatment methods such as physical therapy may provide a valuable therapeutic adjunctive option in patients with CIPN. Physical therapy treatment methods had been shown to produce effective symptom control and enhance quality of life in palliative care. A detailed evidence-based update of literature is provided under evaluation and management of CIPN with a special perspective of physical therapy management using a proposed clinical reasoning-based treatment decision making algorithm so that an Ã¢â‚¬Ëœout of the boxÃ¢â‚¬â„¢ self-reflective evidence-informed critical thinking process is applied along a collaborative multidisciplinary biopsychosocial approach.Ã‚Â Keywords: Chemotherapy-induced neurotoxicity; Chemotherapy-induced neuropathy; Physical therapy; Palliative rehabilitation

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment and Treatment of Chemotherapy-induced Peripheral Neuropathy- a Physical Therapy Perspective

Kumar

Jamwal

2015

GJCT

View full text Add to dashboard Cite

show abstract

“…In some instances, CIPN symptoms may occur gradually over a prolonged period. But it is not uncommon for CIPN symptoms to appear suddenly and intensely (Wilkes, 2007).…”

Section: Effects Of Cipn On Gait and Fall Risk 12mentioning

confidence: 99%

“…Symptoms of CIPN may be acute, mild or severe, transient or chronic, depending upon the treatment regime and dose of the agents and may manifest in a variety of ways, involving sensory and motor symptoms (Park et al, 2013;Postma & Heimans, 2000;Wilkes, 2007).…”

Section: Introductionmentioning

confidence: 99%

“…Motor symptoms may include weakness, balance disturbances, and difficulty performing fine motor skills and a diminished or absent deep tendon reflex. Motor symptoms are less frequent due to the neurotoxic agent's inability to cross the blood-brain barrier in concentrations significant to cause harm (Bakitas, 2007;Murillo, Cox, & Oholendt, 2008;Park et al, 2013;Visovsky, Collins, Abbott, Aschenbrenner, & Hart, 2007;Wilkes, 2007). The autonomic system may also be affected, resulting in constipation, urinary retention, sexual dysfunction, and altered blood pressure (Bakitas, 2007;Visovsky et al, 2007;Wilkes, 2007).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Chemotherapy-Induced-Peripheral-Neuropathy on Spatiotemporal Gait Parameters and Fall Risk in Cancer Patients After the Completion of Chemotherapy Drug Treatment

Marshall

Zipp²,

Battaglia³

et al. 2016

Archives of Physical Medicine and Rehabilitation

View full text Add to dashboard Cite

“…25 The degree and type of peripheral neuropathy depends on the chemotherapy drug, with incidence ranging from 10% to 90% of patients, and with platinum drugs such as oxaliplatin being the most toxic. 26 For most drugs the risk increases with cumulative dose. Typically, the clinical presentation reflects an axonal peripheral neuropathy with glove-and-stocking distribution sensory loss, combined with features suggestive of nerve hyperexcitability, including paresthesia, dysesthesia, and pain.…”

Section: Chemotherapy-induced Peripheral Neuropathymentioning

confidence: 99%

Targeting Neuroprotection as an Alternative Approach to Preventing and Treating Neuropathic Pain

Bordet

Pruss

2009

Neurotherapeutics

View full text Add to dashboard Cite

Summary:Neuropathic pain syndromes arise from dysfunction of the nerve itself, through traumatic or nontraumatic injury. Unlike acute pain syndromes, the pain is long-lasting and does not respond to common analgesic therapies. Drugs that disrupt nerve conduction and transmission or central sensitization, currently the only effective treatments, are only modestly effective for a portion of the patients suffering from neuropathic pain and come with the cost of serious adverse effects. Neurodegeneration, as a reaction to nerve trauma or chronic metabolic or chemical intoxication, appears to be an underlying cause of neuropathic pain. Identifying mechanisms of neurodegeneration and designing neuroprotective therapies is an ambitious goal toward treating or even preventing the development of these disabling disorders.

show abstract

Peripheral Neuropathy Related to Chemotherapy

Cited by 70 publications

References 56 publications

Assessment and Treatment of Chemotherapy-induced Peripheral Neuropathy- a Physical Therapy Perspective

Assessment and Treatment of Chemotherapy-induced Peripheral Neuropathy- a Physical Therapy Perspective

Effects of Chemotherapy-Induced-Peripheral-Neuropathy on Spatiotemporal Gait Parameters and Fall Risk in Cancer Patients After the Completion of Chemotherapy Drug Treatment

Targeting Neuroprotection as an Alternative Approach to Preventing and Treating Neuropathic Pain

Contact Info

Product

Resources

About